Sarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval

September 19, 2016 9:59 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) is up 82% after re-opening on accelerated approval for eteplirsen



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Momentum Movers, Trader Talk, Trading Halts

Add Your Comment